YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Chronic myeloid leukemia cells or CML, analyze by microscope. Blood cancer cells image] Md Ariful Islam/iStock via Getty Images * Enliven Therapeutics (ELVN [https://seekingalpha.com/symbol/ELVN]) and the US FDA have agreed on a design fo…
Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum…
Miners like Southern Copper and Newmont lead this screen of stocks to watch in or near buy range alongside UBS, Garmin and more. Continue Reading
(RTTNews) - As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained…
AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors. Continue Reading
(RTTNews) - The following biotech stocks reached 52-week highs on July 16, 2026, resulting due to anticipated quarterly report releases or an upcoming conference participation. CareDx Inc. (CDNA) CareDx is a precision medicine company spec…
Plus, other significant moves in holdings of Oruka Therapeutics, Enliven Therapeutics, NN, and Alvotech. Continue Reading
Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026, according to a SEC Form 4 filing. Transaction summary…
Key Points A director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000. The sale represented 16.16% of Lori Anne Kunkel’s direct common stock holdings, reduci…
Key Points Orbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share. This transaction represented 11.60% of Advisors Ll…
On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.…
Medical and biotech-focused hedge fund Orbimed Advisors reported a notable sale in Enliven Therapeutics Inc (NASDAQ:ELVN). The clinical-stage biotech is advancing cancer therapies recently annolunced promising data on a leukemia drug it is…
(RTTNews) - Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; a…
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks That Absolutely Exploded Higher. Enliven Therapeutics rallied for a fourth consecutive day on Friday, climbing 14.30 percent to finish at $46.13 apiece, as investor sentiment…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Keefe Bruyette upgraded Toll Brothers(TOL)…
Key Points Exome sold 421,488 shares of Wave Life Sciences; the estimated trade size was $5.49 million based on quarterly average prices. The quarter-end value of the position decreased by $7.17 million as a result. This transaction repres…
On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences(NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million trade based on quarterly average pricing. What happened According to an SEC filing dat…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Enliven Therapeutics Inc (Symbol: ELVN), where a total volume of 16,050 contracts has been traded thus far today, a contr…
Avidity Partners Management disclosed a buy of 259,700 shares of Enliven Therapeutics(NASDAQ:ELVN) in its May 13, 2026, SEC filing, an estimated $7.19 million transaction based on quarterly average pricing. What happened According to a SEC…
Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 milli…
On May 13, 2026, Avidity Partners Management disclosed a new position in Aktis Oncology(NASDAQ:AKTS), acquiring 468,566 shares in the first quarter. The estimated transaction value was $9.10 million based on quarterly average pricing. What…
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The ra…
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen its stock price soar by 194 percent year-to-date, at $45.34 versus $15.40 on December 31, with investor sentiment p…
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its B…
Key Points Helen Louise Collins exercised and sold 40,000 Common Stock shares over March 9–10, 2026, generating proceeds of ~$1.20 million at a weighted average price of $30.07 per share. The transaction reduced her direct Common Stock hol…
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics(NASDAQ:ELVN), reported the exercise of 40,000 stock options for Common Stock and immediate sale of those shares for proceeds of approximately ~$1.20 million, according to…
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks Investors Are Buying Now. Enliven Therapeutics soared to a new five-year high on Wednesday, as investors took heart from two analysts’ optimistic coverage for the stock, with…
(RTTNews) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis. - ScinoPharm secures FDA nod for Glatiramer Acet…
In trading on Tuesday, shares of Enliven Therapeutics Inc (Symbol: ELVN) crossed below their 200 day moving average of $20.03, changing hands as low as $17.31 per share. Enliven Therapeutics Inc shares are currently trading off about 5.9%…
Key Points New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (AUM). The move also marks a…
Key Points New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP’s 13F reportable assets under…
Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable asse…
Key Points New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period. Following the buy, Commodore reported hold…
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT PMNT [h…
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv…
* Enliven Therapeutics (NASDAQ:ELVN [https://seekingalpha.com/symbol/ELVN]) filed automatic mixed securities shelf. * Filing [https://seekingalpha.com/filing/10301128] MORE ON ENLIVEN THERAPEUTICS * Enliven Therapeutics stock falls after p…